Tenecteplase Has Similar Safety to TPA for Acute Ischemic Stroke
By Elana Gotkine HealthDay Reporter
THURSDAY, Oct. 17, 2024 -- For patients with acute ischemic stroke (AIS), tenecteplase (TNK) has improved functional outcome and reduced disability and similar safety to alteplase (tissue plasminogen activator [TPA]), according to a study published online Oct. 16 in Neurology.
Lina Palaiodimou, M.D., Ph.D., from the National and Kapodistrian University of Athens in Greece, and colleagues conducted a systematic review and meta-analysis of all available randomized controlled trials (RCTs) that examined the efficacy and safety of TNK 0.25 mg/kg versus TPA for treatment of AIS within 4.5 hours of onset. Data were included for 11 RCTs, with 3,788 patients treated with TNK and 3,757 patients treated with TPA.
The researchers found that compared with TPA, TNK was associated with a higher likelihood of excellent functional outcome (risk ratio, 1.05) and reduced disability at three months (common odds ratio, 1.10), while the groups had similar improved functional outcome. Similar rates of symptomatic intracranial hemorrhage and three-month mortality were observed in the groups. Statistical significance in achieving an excellent functional outcome at three months was retained for the original TNK when stratified for TNK regimen (original versus biocopy; risk ratio, 1.05).
"It demonstrates that TNK is associated with better clinical outcomes, showing superiority over TPA in achieving excellent functional outcome and reduced disability at three months. These findings support transitioning to TNK in clinical practice," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Pathological Fatigue Common Up to 12 Months After TIA
WEDNESDAY, May 14, 2025 -- Pathological fatigue is common up to 12 months after a diagnosis of transient ischemic attack (TIA), according to a study published online May 14 in...
No Benefit Seen for Revascularization Added to Drug Therapy in Carotid Stenosis
FRIDAY, May 2, 2025 -- For patients with asymptomatic or symptomatic carotid stenosis of 50 percent or greater with a low or intermediate predicted stroke risk, there is no...
Early Combination of Lipid-Lowering Therapy Beneficial After Myocardial Infarction
MONDAY, April 28, 2025 -- For patients with myocardial infarction (MI), early oral combination lipid-lowering therapy (LLT) is beneficial, according to a study published online in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.